ArticleFrontiers in pharmacology2012
Bilirubin, renal hemodynamics, and blood pressure.
Article in Frontiers in pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 27 citations in OpenAlex.
- The HELP-UnaG Fusion Protein as a Bilirubin Biosensor: From Theory to Mature Technological Development.Molecules (Basel, Switzerland) · 2025Review
- Review
- Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1.International journal of molecular sciences · 2022Article
- Translational Approach to the Protective Effect of Bilirubin in Diabetic Kidney Disease.Biomedicines · 2022Review
- Cutting edge concepts: Does bilirubin enhance exercise performance?Frontiers in sports and active living · 2022Review
- Association between serum bilirubin levels and progression of albuminuria in Taiwanese with type 2 diabetes mellitus.Biomedical journal · 2021Article
- Targeting Heme Oxygenase-1 in Cardiovascular and Kidney Disease.Antioxidants (Basel, Switzerland) · 2019Review
- Incidence of neonatal hypertension from a large multicenter study [Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates-AWAKEN].Pediatric research · 2018Article
- Bile cast nephropathy in a patient with cholangiocarcinoma - a case report.Clinical case reports · 2018Article
- Heme oxygenase inhibition increases blood pressure in pregnant rats.American journal of hypertension · 2013Article
- The role of bile pigments in health and disease: effects on cell signaling, cytotoxicity, and cytoprotection.Frontiers in pharmacology · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Bilirubin is generated from the breakdown of heme by heme oxygenase and the reduction of biliverdin by the enzyme biliverdin reductase. Several large population studies have reported a significant inverse correlation between plasma bilirubin levels and the incidence of cardiovascular disease. Protection from cardiovascular disease is also observed in patients with Gilbert's syndrome which is a disease characterized by mutations in hepatic UGT1A1, the enzyme responsible for the conjugation of bilirubin into the bile. Despite the strong correlation between plasma bilirubin levels and the protection from cardiovascular disease, the mechanism by which increases in plasma bilirubin acts to protect against cardiovascular disease is unknown. Since the chronic antihypertensive actions of bilirubin are likely due to its renal actions, the effects of moderate increases in plasma bilirubin on renal hemodynamics as well as bilirubin's potential effects on renal tubule function will be discussed in this review. Mechanisms of action as well as the potential for antihypertensive therapies targeting moderate increases in plasma bilirubin levels will also be highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.